Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Djokovic bets on a COVID cure as he quests for tennis history

Published 19/01/2022, 16:02
Updated 19/01/2022, 18:21
© Reuters. Serbian tennis player Novak Djokovic arrives at Nikola Tesla Airport, after the Australian Federal Court upheld a government decision to cancel his visa to play in the Australian Open, in Belgrade, Serbia January 17, 2022. REUTERS/Christopher Pike

By Nikolaj Skydsgaard

COPENHAGEN (Reuters) - The pandemic has blocked Novak Djokovic's march to tennis history, so the 34-year-old may be pinning his hopes on a cure for COVID to get his hands on another glorious grand slam before time runs out.

The Serbian superstar, who became a focus of the global vaccine debate over his failed attempt to enter Australia without being inoculated, holds a majority stake in a Danish biotech firm aiming to develop a treatment to counter COVID-19, the company's CEO told Reuters.

QuantBioRes boss Ivan Loncarevic, who described himself as an entrepreneur, said the tennis player's acquisition of the 80% stake was made in June 2020 but declined to say how much it was.

The company is developing a peptide, which inhibits the coronavirus from infecting the human cell, expects to launch clinical trials in Britain this summer, according to Loncarevic, who stressed the firm was working on a treatment, not a vaccine.

The CEO said the company had about a dozen researchers working in Denmark, Australia and Slovenia. According to the Danish company register, Djokovic and his wife Jelena own 40.8% and 39.2% of the company, respectively.

A spokesperson for Djokovic did not immediately respond to a request for comment.

Djokovic has enjoyed phenomenal success - Forbes listed him in the world's top-50 highest paid athletes for 2021. It calculated his on-court earnings at $4.5 million, dwarfed by the $30 million it said he earned off court.

Yet time may not be on the world number one's side in his quest to be viewed as the greatest player is history, as he advances deeper into his 30s.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

He had desperately hoped to play in Australian Open this month with his sights firmly set on netting a 21st grand slam title, which would move him above archrivals Roger Federer and Rafa Nadal.

Frustrated Djokovic now risks being frozen out of tennis, with rules on travellers who are unvaccinated tightening in the third year of the pandemic and some tournaments reconsidering exemptions.

The most immediate concern is the next grand slam - the French Open in May where Nadal has already amassed a staggering 13 titles - after the country's sports ministry said on Monday there would be no exemption from a new vaccine pass law.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.